Document Detail


Increased dosage of carbidopa in parkinsonian patients on low carbidopa-levodopa regimen. Effect on levodopa bioavailability.
MedLine Citation:
PMID:  2713868     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The effect of a 2.5-fold increase in daily carbidopa intake on the bioavailability of levodopa was studied in six patients with Parkinson's disease on a low chronic regimen of carbidopa-levodopa (Sinemet) at the fixed ratio of 1:10. The extent of levodopa absorption, expressed as the area under the 11-h plasma levodopa concentration-time curve (AUC0-11 h), was not enhanced by the higher carbidopa dose. A significant increase in the AUC was found for the levodopa metabolite 3-O-methyldopa at the higher carbidopa intake. Clinical performances of individual patients were identical with both carbidopa-levodopa ratios. From these data, an adequate inhibition of peripheral decarboxylation and hence a good bioavailability of levodopa may be expected in patients taking low doses of carbidopa-levodopa, using currently available commercial preparations.
Authors:
M Contin; R Riva; P Martinelli; G Procaccianti; A Baruzzi
Related Documents :
12530108 - Growth discordance and the effect of a male twin on birth weight of its female co-twin:...
15513118 - Laterality of hand, foot, eye, and ear in twins.
4039888 - Interactions between opposite-sex dizygotic fetuses and the assumptions of weinberg dif...
17228158 - Fetus-in-fetu: a rare entity.
20108518 - Management of hyperthyroidism in pregnancy.
1096618 - The influence of advancing gestation on group b streptococcal colonization in pregnant ...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Clinical neuropharmacology     Volume:  12     ISSN:  0362-5664     ISO Abbreviation:  Clin Neuropharmacol     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-06-14     Completed Date:  1989-06-14     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7607910     Medline TA:  Clin Neuropharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  75-81     Citation Subset:  IM    
Affiliation:
Institute of Neurology, University of Bologna, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Aged, 80 and over
Biological Availability
Carbidopa / administration & dosage*,  therapeutic use
Dose-Response Relationship, Drug
Humans
Levodopa / blood,  pharmacokinetics*,  therapeutic use
Male
Middle Aged
Parkinson Disease / drug therapy*
Tyrosine / analogs & derivatives,  blood
Chemical
Reg. No./Substance:
0/Levodopa; 38821-49-7/Carbidopa; 55520-40-6/Tyrosine; 7636-26-2/3-methoxytyrosine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor...
Next Document:  Complete 1H- and 13C-n.m.r. assignments for two sulphated oligosaccharide alditols of hen ovomucin.